United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$302.41 USD
-2.40 (-0.79%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $302.41 0.00 (0.00%) 7:22 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, United Therapeutics Corporation has a market cap of $13.75B, which represents its share price of $304.81 multiplied by its outstanding shares number of 45.11M. As a large-cap company, UTHR's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
UTHR 302.41 -2.40(-0.79%)
Will UTHR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTHR
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
Here's Why United Therapeutics (UTHR) is a Strong Growth Stock
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline
Other News for UTHR
MannKind Corporation: A Post-Q2 Assessment
United Therapeutics (UTHR) Launches $1 Billion Share Buyback
United Therapeutics (UTHR) Launches $1B Stock Buyback Program
United Therapeutics enters $1B accelerated share repurchase program
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program | ...